Table 4.
Maintenance of cardiac treatment in the patients with LVEF recovery after cancer therapy-related cardiomyopathy.
| Drug |
Patients (n = 37) |
p-value | Time (months) |
|---|---|---|---|
| Beta-blockers-n (%) | 37 (100) | 12 [IQR: 7 to 33] | |
| Carvedilol | 31 (83.8) | 0.039 | |
| Bisoprolol | 6 (16.2) | ||
| ACE-I-n (%) | 35 (94.6) | 13 [IQR: 6.8 to 34.5] | |
| Enalapril | 33 (89.2) | 0.24 | |
| Ramipril | 2 (5.4) | ||
| ARB-n (%) | 9 (24.3) | 24 [IQR: 24 to 24] | |
| Valsartan | 4 (10.8) | 0.13 | |
| Losartán | 5 (13.5) | ||
| ARM-n (%) | 13 (35.1) | ||
| Spironolacton | 12 (32.4) | 0.009 | |
| Eplerenone | 1 (2.7) | ||
| Digoxin-n (%) | 4 (10.8) | 14.5 [IQR: 8.8 to 21.8] | |
| Diuretics-n (%) | 16 (43.2) | ||
| Statins-n (%) | 16 (43.2) |
ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blockers; ARM, mineralocorticoid receptor antagonist.
Time refers to the median time that the cardiac-specific treatment was maintained after LVEF recovery.